Gene therapy has the potential to eliminate a number of diseases which are currently causing distress to patients and burden on the healthcare system. Gene therapies have been tested in vitro and were deployed in the clinic for the first time in 2017. The promise of a ‘cure’ has proved tempting for investors and developers alike.
In this editorial feature, we will be discussing current the landscape of gene therapy and existing applications. We will review the unique manufacturing requirements of gene therapies and how developers and vendors are supporting this process. Finally, we will hear from leading experts in the field, who will review ethical and regulatory developments that could impact developers and patients.